Seeking Alpha
We cover over 5K calls/quarter
Profile| Send Message|
( followers)  

Unilife (NASDAQ:UNIS)

Q1 2014 Earnings Call

November 11, 2013 4:30 pm ET

Executives

Todd Fromer - Managing Partner

Alan D. Shortall - Chief Executive Officer, Executive Director, Member of Strategic Partnerships Committee and Chief Executive Officer of UMSL

Ramin Mojdeh - Chief Operating Officer and Executive Vice President

Analysts

Keith Albert Markey - Griffin Securities, Inc., Research Division

Jeffrey S. Cohen - Ladenburg Thalmann & Co. Inc., Research Division

Danielle Antalffy - Leerink Swann LLC, Research Division

Operator

Good day, ladies and gentlemen, and thank you for your patience. You've joined the Unilife Corporation First Quarter Fiscal 2014 Earnings Call. [Operator Instructions] As a reminder, this conference may be recorded.

I would now like to turn the call over to your host, Managing Partner of KCSA, Mr. Todd Fromer. Sir, you may begin.

Todd Fromer

Thank you. Good afternoon, everyone, and good morning to all our Australian supporters. Thank you for joining us to the Unilife Corporation Fiscal 2014 First Quarter Conference Call.

Before we begin today, I would like to remind everyone that this conference call contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate to occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and not on information currently available to our management.

Our management believes that these forward-looking statements are reasonable as of when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements whether as a result of information, future events or otherwise, except as required by law.

In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in Item 1A, Risk Factors, and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports, which we file with the Securities and Exchange Commission.

With nothing further, I would now like to turn the call over to Mr. Alan Shortall, Chief Executive Officer of Unilife. Alan, the floor is yours.

Alan D. Shortall

Thank you, Todd. Good afternoon and good morning to those dialing in from Australia. I'm today joined by our Chief Operating Officer, Dr. Ramin Mojdeh. On this call today, we will discuss how Unilife has passed an inflection point in our business. Our future will be defined by rapid revenue growth. Moving forward, we expect sequential quarterly growth in fiscal year 2014 and significant annual growth year over prior year for fiscal year 2014 and beyond.

In September, we delivered a cornerstone deal with Sanofi. And today, we announced another cornerstone deal with MedImmune, the biologic arm of AstraZeneca. As I've said previously, there is a paradigm shift on the way in the pharmaceutical and health care industries. This shift is being driven by converging market trends, including the rise of biologics, the increasing shift to patient self-injection and the need to generate brand differentiation for drugs in increasingly competitive therapeutic markets.

Unilife identified this shift as a major business opportunity. And we have aggressively invested in R&D to take full advantage. We have addressed these unmet market needs. We have out-innovated and have outperformed the competition. And we are now in full position to capitalize on this new era of injectable drug delivery.

As we continue to lock in customer commitments that will extend for 10, 15 and even 20 years, the advantage gained by our business model, superior technology and service commitment will only further accelerate our competitive position and build value for our shareholders.

So let's take a look at 1 of the 6 platforms in our portfolio. That's our wearable injector platform, where we announced a supply contract with MedImmune earlier today. Before I talk about this contract, I'd like to give you some background on the market, it's projected rate of growth this decade and why we have quickly risen to become the industry leader. Wearable injectors represent a new device class within the $12 billion markets for injectable drug delivery systems. These wearable disposable systems have been developed in response to pharmaceutical requirements for the delivery of a new generation of high-value biologic drugs.

A market research report on wearable injectors published recently by Roots Analysis makes for some interesting reading. Let me share a few of the key points. To date, there is no drug approved for launch in a wearable injector format, but more than 100 biologics are expected to be launched in wearable injectors over the next decade. This industry report shows that some of the most anticipated late-stage pipeline drugs in the pharmaceutical industry are being targeted for launch in wearable injectors. These drugs, which would typically cost hundreds or thousands of dollars a dose, span more than a dozen therapeutic classes, including cancer and autoimmune diseases. Other approved drugs are expected to transition over to the use of a wearable injector as part of life cycle management strategies.

All pharmaceutical customers that have notified Unilife of our selection as a preferred partner have several target drugs in their clinical pipeline targeted for use with wearable injectors, most are biologics that are in late stage clinical development. Typically, around 80% of biologics that reached Phase III will achieve regulatory approval. So there is minimal regulatory risk. Each of these biologics that get approved by the FDA and other regulatory bodies will be classified as a drug device combination product. The wearable injector will be integral to the drug's approval and commercial success. So for each drug that gets approved with our wearable injectors, we are looking at customer commitments that can extend for the entire commercial life cycle. These partnerships will establish commercial partnerships that may last 15 or 20 years.

By 2024, Roots estimates that more than 350 million wearable injectors will be sold annually, with an average selling price per device of between $20 and $35 each. The projected market size is in excess of $8 billion annually.

In the reports-based scenario, they are estimating a compounded annual growth rate of 138% between 2015 and 2020 as the first wave of drugs supplied in the wearable injector hits the market. Then between 2020 and 2024, they estimate things settling down to a still very substantial compounded annual growth rate of 48%. This is the single largest market opportunity for injectable drug delivery systems, and Unilife has taken the lead position in this $8 billion market.

The Unilife portfolio of ReadyToGo wearable injectors is a game changing platform that addresses the unmet needs of biotech customers in delivering high dose volume therapies wherever the patients are. Our wearable injectors are prefilled, preassembled and ready for injection. They're supplied to pharmaceutical companies, ready for integration with their standard filling processes. They utilize standard materials in the primary drug container and they require no terminal sterilization. These are unique competitive advantages that are proprietary to Unilife.

Furthermore, we have the easiest user interface you can imagine. Only 3 simple steps are required for use by the patient. We call it peel, stick and click. Human factor studies consistently show that patients are able to intuitively use the device with minimal or no training. And on-body safety interlock, a Flexwear comfort catheter and an electronic user interface are among an array of other features that maximize patient comfort and awareness during all stages of use. The devices are designed to minimize disruption to a patient's normal daily lifestyle during the period of dose delivery. The electronics in the device can be easily detached and disposed of for markets that require special electronics disposal procedures.

A video about our wearable injectors can be viewed on the Unilife website. I encourage everyone to take a look. Unilife has the best technology, the best expertise in this field and the best execution.

As I am sure you saw this morning, we have announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to customize and supply devices from our platform of wearable injectors for use with molecules in MedImmune's pipeline. This is our first of many wearable injector contracts to emerge from our commercial pipeline.

MedImmune has one of the richest biologic portfolios in the industry, with 120 large molecule drugs in research and development that comprise half of AstraZeneca's total clinical pipeline. MedImmune selected Unilife Technology after an extensive evaluation process to select its partner for the supply of wearable injectors for use with a series of current and future biologic therapies. Under this agreement, Unilife will supply MedImmune with customized devices from our platform of wearable injectors. Several drug candidates from MedImmune's portfolio are expected to be selected for use with our wearable injectors under this agreement.

We have already started to generate revenue beginning in the first quarter of fiscal 2014. We continue to accelerate the expansion of our customer base. Multiple additional customers are in our commercial pipeline. These leading pharmaceutical and biotechnology companies are pursuing and, in many cases, have already selected products from across our 6 platforms. Information regarding each customer partnership will be announced when it can be disclosed.

As I have said all along, fiscal year 2014 is when we begin to show rapidly increasing revenue. As such, we reported revenue of $3.2 million in the first quarter of fiscal year 2014. This is an increase of over 360% over prior-year quarter 1. Although the comparison is against a small base, it is significant in that it shows the inflection point in our revenue, and the slope is significant. As we continue to increase our investment in R&D and operations, which will be increasingly offset by our revenue, we are also narrowing our operating loss.

We have reported a 10% decrease in operating loss in Q1 2014 over the prior year's first quarter. The loss per share has narrowed by 25% over prior year Q1 to $0.12. While investment in R&D is increasing, SG&A expenses remained flat quarter-over-quarter as we continue our commitment to control our G&A. Adjusted net loss for the quarter ended September 30, 2013, was $7.1 million compared to an adjusted net loss of $9.1 million for the same quarter last year, which excludes noncash share-based compensation expense, depreciation, amortization and interest expense.

We continue to manage our cash position to minimize dilution to existing shareholders. As of September 30, 2013, we have $9.4 million in total cash. In addition, I can advise that we have received the first payment of $5 million from Sanofi under the supply agreement for Lovenox. This revenue has not yet been recognized. It was recorded as deferred revenue in the September 30, 2013 balance sheet, however, we have full access to the cash for business operations.

Moving forward, I anticipate sequential quarter-to-quarter growth in fiscal year 2014, as well as significant annual growth year over prior year in fiscal year 2014 and beyond. Although we can be cash flow positive this year if we wanted to do so, it is not in the best long-term interest of our shareholders. That's because limiting our investment in R&D today can dampen the growth we anticipate and slow down programs where we are working in tandem with pharmaceutical customers to customize and supply our devices for use with their approved and late stage drugs.

I would like to reiterate that we are focused on rapid and significant growth in the long term. To accomplish this, we will continue to increase our investment in R&D and operations, much of which will be offset by our increasing revenue.

A look at the breadth and quality of our product portfolio on our website shows how far we have come over the last 2 to 3 years. The results are getting -- the results we are getting from our investment in these areas are tangible in the contracts that we are announcing with pharmaceutical customers, the value of our IP portfolio and the continued growth in our revenue.

Before I open up the call to questions, I would like to add 1 or 2 more quick points. Today, we have provided you with greater clarity on revenue expectations and revenue growth. Previously, I have put out an indication on the number of deals I expect to do this calendar year. All of these deals are in process and will be completed. I look forward to announcing these deals as over the coming months they are completed. At most, we'll include significant upfront and recurring revenues. We have no plans to conduct any significant secondary offering, either now or in the foreseeable future.

Finally, I'd like to note that I have increased my own share position since our last quarterly call, investing an additional $2.3 million through the exercise of options. This was not a cashless exercise. Even though this created an immediate tax liability for me, I have no plans to sell any of my shares. Between my open market purchases and my exercise of options, I have invested over $4.7 million of my own cash since we listed on NASDAQ, increasing my total holdings by over 1.8 million shares. I think this should underline my supreme confidence in our current position, future outlook and overall corporate health.

I would now like to open the call up to questions.

Question-and-Answer Session

Operator

[Operator Instructions] Our first question comes from Keith Markey of Griffin Securities.

Keith Albert Markey - Griffin Securities, Inc., Research Division

A couple of things. I was just wondering, can you give us a sense as to the number of drugs that are included in the MedImmune deal presently?

Alan D. Shortall

I can't actually do that because, obviously, it's confidential, that's MedImmune's confidential information. I would refer you though to the announcement that we made in which it actually says that wearable injectors for use with molecules, that's plural in MedImmune's pipeline.

Keith Albert Markey - Griffin Securities, Inc., Research Division

Right. Yes, I did pick up on that, I just thought maybe you could give us a guidance on it. Then I was also wondering, can you tell us the reason for the increase in the R&D in the quarter? Was that related to the increased revenues that you've booked?

Alan D. Shortall

Keith, I'll pass that question over to Ramin if that's okay.

Keith Albert Markey - Griffin Securities, Inc., Research Division

Sure.

Ramin Mojdeh

Keith, we are increasing our R&D investment, as Alan said, across all the platforms that we have. And this is -- keep in mind that all of our investment in R&D is focused on new products, and these new products are all in direct response to -- on that customer needs. And as a result, all of them are in play with all the customers that we have. So I would say that, broadly, our R&D investment is across all the different platforms that we have.

Keith Albert Markey - Griffin Securities, Inc., Research Division

Okay. So it wasn't specifically tied to an R&D or other customization agreement?

Ramin Mojdeh

Some of them are directly related to customization and development agreements. And some of them are new novel devices that we're developing for new customers.

Keith Albert Markey - Griffin Securities, Inc., Research Division

Okay. And then one last question. Could you give us the number of shares that were used to calculate the per share loss for the quarter?

Alan D. Shortall

Just bear with me one second, Keith. 93.8 million.

Operator

Our next question comes from Michael Cliburn [ph] of VE MicroCap [ph].

Unknown Analyst

For Alan, over the past couple of months, there's been a lot of releases issues in relation to the class action lawsuit against Unilife. Can you give -- can you clarify the company's stance on this action?

Alan D. Shortall

Sure, I can, Michael. I'm happy to do so. This lawsuit is completely baseless. It's just a rehash of another baseless lawsuit that was filed by a former disgruntled employee that was terminated by the company for incompetence. After the complaint was made public, as you probably know, Forbes wrote an article referring to it. We have questions about the motivation behind the Forbes' article and the activities of certain short-sellers targeting Unilife. And I'm confident that we will prevail with regard to the ex-employee's meritless suit. But most of the claims relate to allegations of noncompliance of quality and regulatory requirements during 2011 and 2012 calendar years, which coincide with the tenure of this disgruntled employee. The best way that I can refute these baseless claims is to say that 2 independent regulatory compliance audits were performed on our quality system this year after we terminated the ex-employee. One audit was by the FDA and another was by our notified body in Europe to maintain our ISO 13485 certification. Both audits resulted in 0 observations, meaning no deviations from applicable quality standards were noted. In addition, we are continually being audited by customers like Sanofi and MedImmune, who have been pleased with our quality systems. The recent securities class action lawsuit simply copies the allegations made by the ex-employee and Forbes. Unilife is in full compliance with all applicable regulatory requirements and federal security laws. This lawsuit is a result of trolling for clients by what I would consider ambulance-chasing securities attorneys. Here's an interesting fact, the law firm that has filed the lawsuit is supposedly representing 1 single Unilife shareholder who purchased 1,817 shares for a total investment of less than $7,000. And as we've seen over the past week since the filing of the class action lawsuit, and there is only 1 class action lawsuit, other attorneys have been actively trolling for clients in the hopes of generating fees for themselves. Unfortunately, the U.S. legal system allows scurrilous plaintiff lawyers to advertise for clients and then to bring a lawsuit for the mere cost of the filing fee with the court in the hope that the company will pay them to go away. These cases are not about the plaintiffs, they're all about the lawyers. The people who know me will know that it is my firm view that we will not, at any time, pay $0.01 to settle any of these baseless cases. We will prove in the court of law that we are in compliance in all aspects of our business, that our corporate governance is robust and that we operate the company with a high level of integrity. Most importantly, I want you to know that a class action suit has had no negative impact on our pharmaceutical company relationships. They deal with ambulance-chaser lawsuits all the time and recognize them for the nuisance that they are. Further, the Forbes article and associated claims made by the disgruntled ex-employee probably slowed the signing of some pending contracts down by maybe 4 to 6 weeks, while the customers conducted additional due diligence, which we encouraged. In some cases, we even provided extensive technical documentation highlighting the strength of our quality and management systems and our compliance with all applicable regulatory requirements. Where appropriate, I actually personally attended meetings with senior executives of these pharmaceutical companies. And if anything, this chapter has only helped to deepen the relationships we have with our customers. Many of these relationships have been built over many years. They know our expertise and our capabilities, they are standing by our side and we've lost -- we've not lost 1 anticipated contract from a single customer. Everything is now back on track. And we have lost nothing except for a few weeks in time. So I hope that answers your question.

Operator

Our next question comes from Harris Kalihi [ph] of Full Stop [ph].

Unknown Analyst

Just one question. I just wanted to know, is the supply agreement with MedImmune announced today, is that the pharmaceutical company referred to in the announcement on 9th of the 11th 2012, which is the time we're evaluating the product?

Alan D. Shortall

I like to pass that -- I'll pass that question over to Ramin, if I can.

Ramin Mojdeh

There are a number of pharmaceutical companies that are working with us in our commercial pipeline, and MedImmune is really the first one that has emerged from the pipeline with this type of agreement. That's really the best that we can say. What we said previously was as much as we could disclose in the past, and I can't really tell you if there are any relationship between the 2 agreements. The 2 are now [indiscernible].

Unknown Analyst

And just one other follow-up question. Is it possible to give any guidance as to what stage in the approval process the drugs under these agreements are at, are they late stage, are they stage 2, stage 3?

Ramin Mojdeh

There are multiple drugs, as the announcement says with respect to MedImmune. And MedImmune -- and the stage of these drugs are variable, depending on what particular drug it is. And we're not yet at liberty to disclose any information about the drugs.

Operator

[Operator Instructions] Our next question comes from Jeff Cohen of Ladenburg Thalmann.

Jeffrey S. Cohen - Ladenburg Thalmann & Co. Inc., Research Division

Just a couple. So how should we think about the R&D and SG&A spend throughout the revenue trajectory in fiscal '14 and '15? Should we think of it more as a percentage of revenue, or should we think of it as a growth? How do you see it happening, or how lumpy do you see it happening?

Alan D. Shortall

I think you're going to see it smooth, and you're going to see it increasing. I think it's too early to view it as a percentage of revenue. If you do that, it would look very lumpy. I would say it's probably best to look at it as a percentage growth year-over-year.

Jeffrey S. Cohen - Ladenburg Thalmann & Co. Inc., Research Division

Okay. And Ramin, if you could, could you comment about any updates on any of the other platforms and any new product introductions planned or any line extensions planned?

Ramin Mojdeh

Well, I can say that we have -- our pipeline -- our commercial pipeline is teeming with new opportunities, and you will see them as they emerge from the pipeline and as -- in the appropriate times. And we have a lot of new products that we are introducing to customers. And if you take a look at our website, you'll see -- you'll get a good view of them. And in fact, we might be adding a few additional new products to our website. So that will give you a sense of the breadth of our portfolio and how fast that portfolio is growing. And I'm sure you will be hearing from us as time goes on with additional cornerstone deals that are in our commercial pipeline that are emerging. In terms of expanding our operations, we are expanding our clean room facilities. We are expanding our manufacturing capacity. We are also working with our suppliers as we prime them to increase production and begin to forecast the emerging future needs across all the different platforms. And we're working very actively with suppliers of automated manufacturing equipments as we begin to scale up some of our platforms. So you'll see a whole slew of activities across the entire spectrum of the internal operations and building capacity and seeing the customers coming through the pipeline.

Operator

Our next question comes from Danielle Antalffy with Leerink Swann.

Danielle Antalffy - Leerink Swann LLC, Research Division

Alan, I was hoping you could give a little bit more color on giving your current cash position. How we think about the next 2 quarters, understanding you're not planning to do a capital raise, but can you talk about the sources of cash inflows and how we think about that sort of in the very near term?

Alan D. Shortall

Yes. Look, we've -- as you can see, we're starting to generate revenues from programs that are in play. That will continue. We've said we're going to have a sequential quarterly growth, quarter-over-quarter, in revenues, and that will happen. I've said previously in my earnings call that I had -- we're sitting and I have the aces in my hand, and I played 2 aces with 2 major cornerstone deals, and I still have a full hand of aces. And those aces that I'll play over the coming weeks or months will actually have numerous types of upfront payments, either through exclusivity or access fees, similar to what you saw with the Sanofi deal. And the only reason that I as CEO and our executive team could be comfortable with our current low cash position, if you look over the previous 3 years, the lowest cash position we ever have had was about $18.5 million, $19 million. So historically, we'd never run below that. The only reason we would do it and not have done a secondary offering either on the back of the Sanofi deal or the back of the MedImmune deal was simply because of our confidence of the deals that are in process that we know were going to happen and that are going to deliver upfront funding. I'm making this categorically, we have no intention of doing a secondary offering. And if anybody has any attention of trying to cover short positions or otherwise through a secondary offering, the agreement is not going to happen. We may tip the ATM a little bit here or there as we're getting the deals in place. I don't even have an expectation of even doing that, but it is a nice backup to have, so -- we're not imprudent, but we are sitting, literally, with aces in our hand and we're going to be generating enough money, upfront money.

Danielle Antalffy - Leerink Swann LLC, Research Division

Got it. And Alan, just to follow up on the wearable injector. Can you talk about the margins on that product and how we think about the impact to margins in 2014 now that you have this MedImmune deal signed and the customization revenue is coming in?

Alan D. Shortall

Well, okay, look, what I'd like to point out, first of all, is that just the wearable injector market, just by the report that's gone out recently, this is an $8 billion a year market inside the next 10 years. Our selection by MedImmune clearly is a very strong indication, having done extensive due diligence over the last 18 months, 2 years, showing that we will be the leader and dominant player, strong player certainly, in this market sector, an $8 billion a year market. Now with that in mind, I'm not going to talk about gross margins, I don't do that. We have said to the market that we are targeting operating margins north of 40%. We're competitively priced with all our devices, including our wearable injectors, for all our pharmaceutical customers. The reason why we can say we're going to be generating operating margins north of 40% is because our -- this is business-to-business model. We lock in long term 10, 15, 20-year supply agreements so our actual sales and marketing costs will only ever be less than 1% of our revenues. That's why we can add real value to our pharmaceutical customers, give them real value for money in terms of the devices we provide them, but on the other hand, perform outstandingly for our shareholders by operating margins of north of 40%.

Operator

Our next question comes from Keith Markey of Griffin Securities.

Keith Albert Markey - Griffin Securities, Inc., Research Division

Just a follow-up question. Ramin, after you mentioned the plans that you have underway or have for expanding your capacity, I was wondering if you could give us a little bit of information about the capital expenditure budget for this year or -- and for next?

Ramin Mojdeh

Well, I won't be able to give you any specific numbers. They're all well planned out. There's capital expenditure -- increasing capital expenditure related to the equipments, related to finishing out our clean room space, which is essentially doubles our clean room space area, and also, some capital equipments related to some of the capital that we would have, such as tooling and molds in our -- some of our suppliers. So it's really a combination of those. It's not all a one-time event. This is really a gradual increase over time because of the nature of how these orders are made and how the money is spent, and also has to do with the timing of the scale up that we have. There are various stages of scale up that we have. Keep in mind that we have a significant amount of manufacturing space already finished that we're operating from, so we're actually taking full advantage of that and getting 200% utilization of that. As in parallel, we gradually build out the rest of the space and begin to add capacity. So this is not a shock to our system. This is something that's well planned out. And as you'll see in our future financials, you'll see a very nice and gradual and well-anticipated ramp. And much of which, if not all of which, is offset by cash receipts that we received from customers under various programs or under some of the deals that we have with our customers. There are some deals, for example, that we have our customers -- we have with our customers that actually have payments associated with the commercial scale up of products. I just want to point that out as one of the key -- one of the many ways in which we fund this kind of expansion as well. So it's really a combination of all of these things. And again, it's well programmed in our financials, in our pro forma financials.

Operator

At this time, I'd like to turn the call back over to management for any closing remarks.

Alan D. Shortall

And thank you, appreciate it. So thank you, everybody, for tuning in. We look forward to sharing more news with you in the near future. And as a final reminder, please don't forget to cast your votes for the upcoming Annual General Meeting. The deadline for voting is Thursday, November 21 in the U.S. and Sunday, November 17 in Australia. And again, I reiterate, I'm sitting with a full hand of aces, and we are in a very strong position as a company and it's an exciting time for us and our shareholders. Thank you.

Operator

Thank you, sir. And thank you, ladies and gentlemen, for your participation. That does conclude your program. You may disconnect your lines at this time. Have a great day.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!

Source: Unilife Management Discusses Q1 2014 Results - Earnings Call Transcript
This Transcript
All Transcripts